Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Other

Duke University

Miles Inc.

Zymogentics, Inc.

Genetics Corporation

Anthony W Siadak

Shirley A Rene

Janine M Bilsborough

Alejandro A Aruffo

Wayne R Kindsvogel

Wenfeng Xu

Stacey R Dillon

Yasmin A Chandrasekher

Margaret Dow Moore

Joyce M Lehner

Pallavur V Sivakumar

Jurgen Bajorath

Mae Joanne Rosok

Diane Hollenbaugh

Barbara A Thorne

Linda Harris

Karen K Berry

Zhi Chen

Steven D Hughes

Michael A Bowen

Jeffry Dean Watkins

Barton F Haynes

William D Huse

Herren Wu

Lieping Chen

Hans Marquardt

Lisa K Gilliland

Dhavalkumar D Patel

Diane L Hollenbaugh

Mark E Lostrom

Robert S Mittler

Walter W Shuford

John E Skonier

Dale L Bodian

Gary C Starling

N Jan Chalupny

John A Gebe

Linda J Harris

Pallavar V Sivakumar

Marcia L Gordon

Shirley Rene

Aaron C Haran

Elin Florkiewicz

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein Vand Vdomains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides. The invention further provides the amino acid sequences of the variable regions of the monoclonal antibodies and use of these monoclonal antibody or antibody fragment in conjunction with an human IgG4 Fc molecule.

Use of IL-31 monoclonal antibodies for treating pruritus

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.

Use of IL-31 monoclonal antibodies for reducing pruritus

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Methods of treating atopic dermatitis with IL-31 monoclonal antibodies

Method of reducing pruritus using IL-31 monoclonal antibodies

Method of treating atopic dermatitis with IL-31 monoclonal antibodies

Polynucleotides encoding IL-31 monoclonal antibodies

IL-31 monoclonal antibodies

Variable region sequences of IL-31 monoclonal antibodies and methods of use

The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

Anti-IL-20 antibodies and binding partners and methods of using in inflammation

Method of reducing pruritis using IL-31 monoclonal antibodies

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

Methods of producing anti-IL-22RA antibodies

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides. The invention further provides the amino acid sequences of the variable regions of the monoclonal antibodies and use of these monoclonal antibody or antibody fragment in conjunction with an human IgG4 Fc molecule.

Anti-IL-22RA antibodies and binding partners and methods of using in inflammation

Growing community of inventors

Seattle, WA, United States of America

Anthony W Siadak